Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;27(5):1505-1513.
doi: 10.1007/s10741-021-10165-y. Epub 2021 Aug 30.

Echocardiographic assessment of cardiac amyloidosis

Tanushree Agrawal  1 , Sherif F Nagueh  2
Affiliations
Review

Echocardiographic assessment of cardiac amyloidosis

Tanushree Agrawal et al. Heart Fail Rev. 2022 Sep.

Abstract

Cardiac amyloidosis, a form of infiltrative cardiomyopathy, is associated with poor prognosis in untreated patients. Early diagnosis is important for timely initiation of effective therapies. Despite advances in diagnostic modalities, it remains a challenging diagnosis, requiring high index of clinical suspicion. Echocardiography represents the first-line cardiac imaging modality for evaluation of heart failure and suspected cardiac amyloidosis. In this review, we discuss echocardiographic findings in cardiac amyloidosis.

Keywords: Cardiac amyloidosis; Echocardiography; Heart failure; Restrictive cardiomyopathy.

PubMed Disclaimer

References

    1. Sipe JD, Benson MD, Buxbaum JN et al (2014) Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 21(4):221–224. https://doi.org/10.3109/13506129.2014.964858 - DOI - PubMed
    1. Smith TJ, Kyle RA, Lie JT (1984) Clinical significance of histopathologic patterns of cardiac amyloidosis. Mayo Clin Proc 59(8):547–555. https://doi.org/10.1016/s0025-6196(12)61493-1 - DOI - PubMed
    1. Ladefoged B, Dybro A, Povlsen JA, Vase H, Clemmensen TS, Poulsen SH (2020) Diagnostic delay in wild type transthyretin cardiac amyloidosis - a clinical challenge. Int J Cardiol 304:138–143. https://doi.org/10.1016/j.ijcard.2019.12.063 - DOI - PubMed
    1. Adams D, Gonzalez-Duarte A, O’Riordan WD et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379(1):11–21. https://doi.org/10.1056/NEJMoa1716153 - DOI - PubMed
    1. Benson MD, Waddington-Cruz M, Berk JL et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379(1):22–31. https://doi.org/10.1056/NEJMoa1716793 - DOI - PubMed

MeSH terms

LinkOut - more resources